| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Nifedipine | N-Nitroso Nifedipine | VE0011075 | View |
| Nifedipine | Nifedipine EP Impurity C | VL1170003 | View CAS 111304-31-5 |
| Nifedipine | Nifedipine EP Impurity D | VL1170004 | View CAS 14205-39-1 |
| Nifedipine | Nifedipine EP impurity A | VL1170002 | View CAS 67035-22-7 |
| Nifedipine | Nifedipine EP impurity B | VL1170001 | View |
| Nifedipine | Nifedipine Pyrimidine Impurity | VL1170005 | View CAS 80742-11-6 |
| Nifedipine | 2-Nitrobenzaldehyde | VE009550 | View CAS 552-89-6 |
| Catalogue No. | VL1170003 |
| CAS No. | 111304-31-5 |
| Molecular Formula | C12H11NO5 |
| Molecular Weight | 249.23 |
| Parent drug | Nifedipine |
| IUPAC Name | 2-[(2-nitrophenyl)methylene]-3-oxo-, methyl ester |
| Synonyms | N/A |
| References | “Validation of an HPLC Method for Nifedipine and Its Related Substances in Raw Materials.” Journal of Liquid Chromatography, 2021, http://www.tandfonline.com/doi/abs/10.1080/01483919108049311.?Sorkin, E. M., et al. “Nifedipine a Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy, in Ischaemic Heart Disease, Hypertension and Related Cardiovascular Disorders.” Drugs, vol. 30, no. 3, Sept. 1985, pp. 182–274, https://doi.org/10.2165/00003495-198530030-00002.? |
| Status | In-stock |
| ListName | Nifedipine EP Impurity C |
| Exclusively Supplied by Veeprho | Exclusively Supplied by Veeprho |
"*" indicates required fields
